Mode
Text Size
Log in / Sign up

Systematic review on quinolone-phage synergy mechanisms and clinical strategiesPhages and antibiotics team up to fight superbugs

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the proposed PAS framework for quinolones, but recognize evidence certainty depends on underlying study quality.

This is a systematic review of mechanisms and strategies for phage-antibiotic synergy (PAS) with quinolone antibiotics and bacteriophages. The review synthesizes evidence on synergistic effects, which manifest across multiple dimensions: bacterial morphological remodeling, activation of temperate phages, disruption of biofilm barriers, potentiation of functional proteins, dual regulation of resistance evolution, and synergy with the host immune system. It also identifies antagonistic effects, primarily triggered by high-concentration antibiotics interfering with phage proliferation, adaptive phenotypic alterations of bacteria, and imbalanced administration strategies.

The authors do not report pooled effect sizes, p-values, confidence intervals, or absolute numbers, as this is a qualitative synthesis of mechanisms. The review provides a framework to guide the standardized clinical application of quinolone-based PAS, including sequential administration, sub-inhibitory antibiotic concentrations paired with minimum effective MOI of phages, rational selection of phages, and individual regimen tailoring.

Key limitations noted are that the evidence is synthesized from reviewed studies, and certainty depends on the quality of the underlying primary studies, which is not assessed in this abstract. The review does not establish causation from primary trials. Practice relevance is restrained to a conceptual framework, as specific clinical efficacy or safety outcomes cannot be inferred from this synthesis.

Drug-resistant bacteria are a growing threat, making common infections harder to treat. But a new review of existing research suggests a surprising ally: bacteriophages, viruses that naturally attack bacteria. When paired with quinolone antibiotics, phages can help overcome resistance in several ways.

The review found that this combination, called phage-antibiotic synergy, works by remodeling bacterial cells, activating dormant phages inside bacteria, breaking down protective biofilms, and even boosting the immune system. These effects can slow the evolution of resistance.

However, it's not always a win. High doses of antibiotics can actually interfere with phage activity, and bacteria can adapt in ways that block the synergy. The key, researchers say, is careful timing and dosing: using lower antibiotic levels and the right amount of phages.

This is a systematic review, meaning it summarizes findings from many studies, but it doesn't provide new clinical trial data. The evidence is promising but early, and more research is needed to turn this into real-world treatments.

What this means for you:
Phages can boost antibiotic power against superbugs, but only with the right strategy.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
The escalating global crisis of bacterial antimicrobial resistance (AMR) has significantly limited the clinical efficacy of quinolone antibiotics, while the use of phages alone suffers from inherent limitations, including a narrow host spectrum and the propensity to rapidly induce phage resistance. Consequently, combined antimicrobial therapy, defined as phage-antibiotic synergy (PAS), has emerged as a pivotal direction to address the challenges. The specific objectives of this review are to systematically dissect the bidirectional synergistic and antagonistic interactions between quinolone antibiotics and bacteriophages, define the key regulatory factors governing their combined effects, and establish an evidence-based framework to guide the standardized clinical application of quinolone-based PAS. This paper systematically reviews the mechanisms underlying the synergistic and antagonistic interactions between quinolone antibiotics and bacteriophages. The synergistic effects are manifested across multiple dimensions: bacterial morphological remodeling, activation of temperate phages, disruption of biofilm barriers, potentiation of functional proteins, dual regulation of resistance evolution, and synergy with the host immune system. In contrast, antagonistic effects are primarily triggered by high-concentration antibiotics interfering with phage proliferation, adaptive phenotypic alterations of bacteria, and imbalanced administration strategies. Simultaneously, we summarize standardized clinical optimization strategies, including sequential administration, sub-inhibitory antibiotic concentrations paired with the minimum effective multiplicity of infection (MOI) of phages, rational selection of broad-host-range and highly lytic phages, and individual regimen tailoring to match the specific infectious scenario and host immune status. We further analyze key challenges in the clinical translation of this therapeutic approach and propose future research directions, offering a framework to guide both mechanistic studies and clinical implementation of PAS as a strategy to mitigate antimicrobial resistance.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.